Watch Ticker

Fennec Pharmaceuticals Inc. Common Stock

Go to Fennec Pharmaceuticals Inc. Common Stock Website

$8.17

0.00 (0.00%)

Live

Previous Close

$8.17

Day Range

$0 - $0

Previous Day Range

$7.94 - $8.51

Market Cap

$229.8 million USD

Day Vol.

Previous Day Vol.

74224

Currency

USD

Primary Exchange

Nasdaq

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The comp...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.

Related tickers: FENC.

Read Full Article

Fennec Pharmaceuticals Inc. - Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec Pharmaceuticals' PEDMARQSI has been approved in the EU and U.K. as the first and only therapy to prevent hearing loss caused by cisplatin chemotherapy in pediatric patients with solid tumors. Norgine Pharmaceuticals has launched PEDMARQSI in Germany, accelerating its global commercialization.

Related tickers: FENC.

Read Full Article

Trending Tickers

Please sign in to view